(Circulation. 1999;99:2892-2900.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Clinical Significance of Thrombocytopenia During a Non–ST-Elevation Acute Coronary Syndrome
The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience
From the Duke Clinical Research Institute (M.W.M., S.D.B., R.S., R.T., L.G.B., R.M.C., R.A.H.), Durham, NC; Methodist Hospital (N.S.K.), Houston, Tex; Cleveland Clinic Foundation (A.M.L., E.J.T.), Cleveland, Ohio; Cardialysis (J.D.), Rotterdam, Netherlands; Estudios Cardiologicos Latinoamerica (R.D.), Rosario, Argentina; Eberhard Karls University (K.R.K.), Tubingen, Germany; COR Therapeutics (D.G., M.K.), South San Francisco, Calif; and Thoraxcenter University Hospital (M.S.), Rotterdam, Netherlands.
Correspondence to Robert A. Harrington, MD, Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27705. E-mail Harri019{at}mc.duke.edu
Background—The significance of thrombocytopenia in patients experiencing an acute coronary syndrome (ACS) has not been examined systematically. We evaluated this condition in a large non–ST-elevation ACS clinical trial, with particular interest paid to its correlation with clinical outcomes.
Methods and Results—Patients presenting without persistent ST elevation during an ACS were randomized to receive a double-blind infusion of the platelet glycoprotein (GP) IIb/IIIa inhibitor eptifibatide or placebo in addition to other standard therapies including heparin and aspirin. The primary end point was death/nonfatal myocardial infarction (MI) at 30 days, whereas bleeding and stroke were the main safety outcomes. Thrombocytopenia (nadir platelet count <100x109/L or <50% of baseline) occurred in 7.0% of enrolled patients. The time to onset was a median of 4 days in both treatment arms. Patients with thrombocytopenia were older, weighed less, were more likely nonwhite, and had more cardiac risk factors. These patients experienced significantly more bleeding events: they were more than twice as likely to experience moderate/severe bleeding after adjustment for confounders. Univariably, ischemic events (stroke, MI, and death) occurred significantly (P<0.001) more frequently in patients with thrombocytopenia; multivariable regression modeling preserved this association with death/nonfatal MI at 30 days. Neither the use of heparin or eptifibatide was found to independently increase thrombocytopenic risk.
Conclusions—Although causality between thrombocytopenia and adverse clinical events could not be established definitively, thrombocytopenia was highly correlated with both bleeding and ischemic events, and the presence of this condition identified a more-at-risk patient population.
Key Words: platelets • eptifibatide • glycoproteins • angina • myocardial infarction • coronary artery disease
This article has been cited by other articles:
 |
|
 |
|
  T. Y. Wang, F.-S. Ou, M. T. Roe, R. A. Harrington, E. M. Ohman, W. B. Gibler, and E. D. Peterson Incidence and Prognostic Significance of Thrombocytopenia Developed During Acute Coronary Syndrome in Contemporary Clinical Practice Circulation, May 12, 2009; 119(18): 2454 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 670S - 707S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. F. Oliveira, E. M. Crespo, R. C. Becker, E. F. Honeycutt, C. S. Abrams, K. J. Anstrom, P. B. Berger, L. D. Davidson-Ray, E. L. Eisenstein, N. S. Kleiman, et al. Incidence and Prognostic Significance of Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy Arch Intern Med, January 14, 2008; 168(1): 94 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. V.K. Naina, S. Harris, A. C. Matzdorff, R. Cathomas, A. Goldhirsch, R. von Moos, R. H. Aster, and D. W. Bougie Drug-Induced Immune Thrombocytopenia N. Engl. J. Med., November 1, 2007; 357(18): 1869 - 1871. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
 |
|
 H. V. K. Naina, S. Harris, and A. Singla Timing of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes JAMA, July 4, 2007; 298(1): 37 - 37. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chevoya and S. Housholder-Hughes Anticoagulant and antiplatelet medications. Crit. Care Nurse, June 1, 2006; 26(3): 19 - 20. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Patel, M. Patel, I. Din, C. V. R. Reddy, and J. Kassotis Profound Thrombocytopenia Associated with Tirofiban: Case Report and Review of Literature Angiology, May 1, 2005; 56(3): 351 - 355. [Abstract] [PDF]
|
|
|
|
|
|
W. H. Matthai Jr Thrombocytopenia in Cardiovascular Patients: Diagnosis and Management Chest, February 1, 2005; 127(2_suppl): 46S - 52S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Aster Immune Thrombocytopenia Caused by Glycoprotein IIb/IIIa Inhibitors Chest, February 1, 2005; 127(2_suppl): 53S - 59S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Harrington, R. C. Becker, M. Ezekowitz, T. W. Meade, C. M. O'Connor, D. A. Vorchheimer, and G. H. Guyatt Antithrombotic Therapy for Coronary Artery Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 513S - 548S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Merlini, M. Rossi, A. Menozzi, S. Buratti, D. M. Brennan, D. J. Moliterno, E. J. Topol, and D. Ardissino Thrombocytopenia Caused by Abciximab or Tirofiban and Its Association With Clinical Outcome in Patients Undergoing Coronary Stenting Circulation, May 11, 2004; 109(18): 2203 - 2206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Williams, L. V. Damaraju, M. A. Mascelli, E. S. Barnathan, R. M. Califf, M. L. Simoons, E. N. Deliargyris, and D. C. Sane Anti-Platelet Factor 4/Heparin Antibodies: An Independent Predictor of 30-Day Myocardial Infarction After Acute Coronary Ischemic Syndromes Circulation, May 13, 2003; 107(18): 2307 - 2312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Seiffert, A. M. Stern, W. Ebling, R. J. Rossi, Y. C. Barrett, R. Wynn, G. F. Hollis, B. He, C. J. Kieras, D. L. Pedicord, et al. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia Blood, January 1, 2003; 101(1): 58 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Bougie, P. R. Wilker, E. D. Wuitschick, B. R. Curtis, M. Malik, S. Levine, R. N. Lind, J. Pereira, and R. H. Aster Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa Blood, August 28, 2002; 100(6): 2071 - 2076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Cohen, D. G. Murphy, and J. Williams Review of the Current ACS Practice Guideline to Develop an Ischemic Chest Pain Protocol Journal of Pharmacy Practice, June 1, 2002; 15(3): 250 - 266. [Abstract] [PDF]
|
|
|
|
|
|
J. T. Billheimer, I. B. Dicker, R. Wynn, J. D. Bradley, D. A. Cromley, H. E. Godonis, L. C. Grimminger, B. He, C. J. Kieras, D. L. Pedicord, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated Blood, May 15, 2002; 99(10): 3540 - 3546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Eikelboom, S. S. Anand, S. R. Mehta, J. I. Weitz, C. Yi, and S. Yusuf Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation : Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Study Circulation, February 6, 2001; 103(5): 643 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Chew and D. J. Moliterno A critical appraisal of platelet glycoprotein IIb/IIIa inhibition J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2028 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Roe, R. A. Harrington, D. M. Prosper, K. S. Pieper, D. L. Bhatt, A. M. Lincoff, M. L. Simoons, M. Akkerhuis, E. M. Ohman, M. M. Kitt, et al. Clinical and Therapeutic Profile of Patients Presenting With Acute Coronary Syndromes Who Do Not Have Significant Coronary Artery Disease Circulation, September 5, 2000; 102(10): 1101 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Braunwald, E. M. Antman, J. W. Beasley, R. M. Califf, M. D. Cheitlin, J. S. Hochman, R. H. Jones, D. Kereiakes, J. Kupersmith, T. N. Levin, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) J. Am. Coll. Cardiol., September 1, 2000; 36(3): 970 - 1062. [Full Text] [PDF]
|
|
|
|
|
|
R. A. Harrington, P. W. Armstrong, C. Graffagnino, F. Van de Werf, D. J. Kereiakes, K. N. Sigmon, T. Card, D. M. Joseph, R. Samuels, J. Granett, et al. Dose-Finding, Safety, and Tolerability Study of an Oral Platelet Glycoprotein IIb/IIIa Inhibitor, Lotrafiban, in Patients With Coronary or Cerebral Atherosclerotic Disease Circulation, August 15, 2000; 102(7): 728 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Poullis and I. Malik Thrombocytopenia and Glycoprotein IIb/IIIa Inhibitors: Causation or Association? Circulation, June 27, 2000; 101 (25): e241 - e241. [Full Text] [PDF]
|
|